NRGene wins $250K Grow-NY grant to bring insect protein to Upstate New York
What's the deal? Saskatoon-based NRGene CanadaDealroom has a profile for this one. Try Dealroom → has won a US$250,000 grant from Empire State DevelopmentDealroom has a profile for this one. Try Dealroom →'s eighth annual Grow-NYDealroom has a profile for this one. Try Dealroom → competition, one of seven winners to share US$3 million. The award backs its model for converting food and beverage by-products into premium feed using AI-selected black soldier fly genetics.
What's the endgame? NRGeneDealroom has a profile for this one. Try Dealroom → runs an asset-light, hub-and-spoke network: host businesses such as wineries, breweries, and dairy processors run compact rearing units on their own sites. The company supplies young larvae and training, then buys back the output to sell under its MaxBites and MaxFrass brands. It says its MaxBSF strain delivers up to 2.1 times the output of industry-standard lines.
Why now? The grant marks NRGene's first concrete step into the US market. It has signed letters of intent with three Upstate New York businesses and is exploring others across the Grow-NY region's 22 counties.
What's the context? The model is already operating in Canada. MaxBites insect treats are on retail shelves across Western Canada, a FairGene joint venture in Alberta supplies larvae to partner sites, and a semi-industrial trial in northern Saskatchewan turned fish-processing by-product into omega-3-rich larvae.
Chief business officer Yossi Levi said winning Grow-NY is "a strong vote of confidence in our approach," adding that "Upstate New York is where we plan to begin in the U.S."
What could go wrong? The letters of intent are not yet operating contracts. Winners commit to a 12-month regional impact, so the award's significance depends on converting local partnerships into production and sales.
The signal: Grow-NY, funded by Empire State Development and administered by Cornell University, drew 334 applicants from 49 countries this year. Its backing of insect-protein and waste-to-value ventures reflects growing investor appetite for circular agrifood models — though for NRGene, the grant is useful expansion capital and validation, not yet a scaled US business.
Read more: pr.southjordanjournal.com
Image credit: Generated with Gemini